Emerging biomarkers
Many new players are emerging and biomarkers
of cardiac remodelling could provide additional
information to natriuretic peptides testing and
help to develop more tailor-based strategies for
treatment. 2,3 As previously mentioned, the
remodelling and fibrosis of the heart plays an
important role in the progression of HF.
Biomarkers related to cardiac hypertrophy,
cardiac fibrosis and remodeling of the
extracellular matrix could provide valuable
information for the risk stratification of HF
patients. Soluble ST2 and fibroblast growth factor
23 (FGF-23) are two good examples of biomarkers
related to remodelling, and automated assays are
emerging to facilitate their measurement in
clinical laboratories. 4–8
Soluble ST2
Interleukin 33 (IL-33) is a member of the IL-1
cytokine family acting both as a cytokine and
as an intracellular nuclear factor with
transcriptional regulatory properties. IL-33
prevents the apoptosis of cardiomyocytes and
improves cardiac function and survival after
myocardial infarction through ST2 signalling. 4,7
ST2 is a receptor encoded by IL1RL1 and for which
differential splicing of the gene can produce
a functional membrane-bound receptor (ST2L)
or a soluble decoy receptor (sST2) able to quench
the biological activity of IL-33. The increase of
circulating sST2 levels is related to cardiac
remodelling, fibrosis and HF, and measurement
of sST2 could facilitate the risk stratification and
treatment of HF with reduced ejection fraction
as well as the diagnosis and prognosis of HF with
preserved ejection fraction. 4,7,9
FGF-23
FGF-23, a key regulator of the phosphorus
homeostasis, is produced by osteocytes and binds
to renal and parathyroid FGF-Klotho receptor
heterodimers, resulting in phosphate excretion,
decreased 1-a-hydroxylation of 25-hydroxyvitamin
D and decreased parathyroid hormone (PTH)
secretion. 5,6 As for PTH, impaired homeostasis
of cations and decreased glomerular filtration
rate might contribute to the rise of FGF-23. The
amino-terminal portion of FGF-23 (amino acids
1–24) may serve as a signal peptide allowing the
secretion into the blood, and the carboxyl-
terminal portion (amino acids 180–251)
participates in its biological action. FGF-23 is also
related to the risk of cardiovascular diseases and
mortality. 5,6 FGF-23 levels are independently
associated with left ventricular mass index and
hypertrophy as well as mortality in patients with
chronic kidney disease. Increased circulating
concentrations of FGF-23 are independently
associated with the risk of developing HF in
the community and with poor clinical outcome
in HF patients, and assays for the measurement
of circulating concentrations of the intact
hormone (iFGF-23) and some against the
C-terminal fragments of FGF-23 (Ct-FGF-23) are
available.
Perspectives from emerging technologies
Progress around point of care testing (POCT)
technologies is enormous, contributing to
increasing their reliability and the number of
tests available. 2,7,10 The added value of POCT is
increasingly evident for rapid diagnosis and
might add value in primary care and pre-hospital
settings. An example is illustrated by the
integration of tele-cardiology units and central
laboratories through cardiac markers performed
with POCT technologies in the ambulance. 10
These procedures can play an important role
in the early diagnosis and treatment of acute
coronary syndrome patients related to the
pre-hospital phase. The performances of some
POCT assays are now compatible with the
enquiries of physicians for the management and
monitoring of HF, and both BNP and NT-proBNP
can be determined by POCT assays. The
implementation of POCT will of course rely on
interactions between laboratory specialists and
users to respect the requirements of accreditation
standards and to maximise the efficiency of
POCT-based protocols. 7,10
Beside the shift of paradigm for biomarker
testing, recent progress in the area of mobile
Health (mHealth) is also spectacular. 10 MHealth
describes the use of portable electronic devices
with software applications to
provide health services and manage patient
information. With approximately five billion
mobile phone users globally, mHealth
technologies have the potential to greatly
impact health research, health care, and health
outcomes. Mobile phones, smartphones, and
tablets are therefore exceptional means for the
empowerment of patients with chronic illness.
The use of mHealth technologies decreases the
number of disease-rel ated health outcomes in
Beside the shift of paradigm
for biomarker testing, recent
progress in the area of mobile health
(mHealth) is also spectacular
patients suffering from chronic diseases
compared with regular care. 10 In HF patients,
mHealth aid in decreasing the length of stay
in hospitals and in maintaining the activities
of daily living. Studies involving patients with
hypertension also demonstrated the ability of
mHealth to reduce systolic and/or diastolic
blood pressure. 10
Innovations are also coming from the field of
data mining and integration, which will allow the
combination of clinical and biological features for
a more accurate management of patients and will
facilitate the identification of clusters of patients
at higher risk or more suitable for selection for
clinical trials.
Conclusions
To reach maximum potential, innovative
biomarkers and emerging technologies will
require a multidisciplinary assessment of
technical, clinical and economical outcomes,
meaning that the communication between
specialists in laboratory medicine and other
healthcare professionals will be needed to ensure
an efficient translation into daily practice.
54
HHE 2018 | hospitalhealthcare.com
References
1 Timmis A et al. European
Society of Cardiology:
Cardiovascular Disease Statistics
2017. Eur Heart J 2018;39(7):
508–79.
2 Gruson D, Thys F, Verschuren
F. Diagnosing destabilized
heart failure in the emergency
setting: current and future
biomarker tests. Mol Diagn Ther
2011;15(6):327–40.
3 Gruson D, Ko G. Galectins
testing: new promises for the
diagnosis and risk stratification
of chronic diseases? Clin
Biochem 2012;45(10-11):
719–26.
4 Gruson D et al. Increased
soluble ST2 is a stronger
predictor of long-term
cardiovascular death than
natriuretic peptides in heart
failure patients with reduced
ejection fraction. Int J Cardiol
2014;172(1):e250–2.
5 Gruson D et al. Comparison
of fibroblast growth factor 23,
soluble ST2 and Galectin-3
for prognostication of
cardiovascular death in heart
failure patients. Int J Cardiol
2015;189:185–7.
6 Gruson D et al. Head to head
comparison of intact and
C-terminal fibroblast growth
factor 23 in heart failure patients
with reduced ejection fraction.
Int J Cardiol 2017;248:270–3.
7 Gruson D et al. Testing for
soluble ST2 in heart failure
patients: Reliability of a point
of care method. Clin Lab
2017;63(1):141–5.
8 Lepoutre T et al. Measurement
Nt-proBNP circulating
concentrations in heart failure
patients with a new point-of-
care assay. Clin Lab 2013;59
(7-8):831–5.
9 Gruson D et al. Increased
soluble ST2 is a stronger
predictor of long-term
cardiovascular death than
natriuretic peptides in heart
failure patients with reduced
ejection fraction. Int J Cardiol
2014;172(1):e250–2.
10 Gruson D, Ko G. Laboratory
medicine and mobile
health technologies at
crossroads: Perspectives for
the management of chronic
diseases. Crit Rev Clin Lab Sci
2016;53(5):352–7.